Male breast cancer -: A reappraisal of clinical and biologic indicators of prognosis

被引:17
作者
André, S [1 ]
Fonseca, I [1 ]
Pinto, AE [1 ]
Cardoso, P [1 ]
Pereira, T [1 ]
Soares, J [1 ]
机构
[1] Inst Porgugues Oncol Francisco Gentil, Ctr Lisboa, Dept Pathol Morfol, P-1099023 Lisbon, Portugal
关键词
D O I
10.1080/028418601750288190
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Between 1970 and 1998, 90 cases of male breast cancer with available pathological material were retrieved. The disease often presented in aged patients (median-66 years) and as advanced stage (stage III/IV-51%). Excluding stage IV disease. the neoplasia were predominantly ductal invasive carcinomas, NOS (not otherwise specified) (92%), grade I and grade 2 (94%), positive for estrogen and progesterone receptors (72% and 74%), negative for androgen receptors (100%), p53 negative (95%), c-erbB-2 negative (88%) and DNA aneuploid (73%). Assessment of disease outcome is determined by stage at time of diagnosis, and axillary lymph node status was the only parameter found to have a statistically significant correlation with either disease-free interval or overall survival (p < 0.001) by multivariate analysis. Clinically useful information on the probability of relapse can be added by determining c-erbB-2 (p = 0.02) an progesterone receptors (p = 0.04) in stage III and tumor ploidy (p = 0.04) in pN1 subgroups of patients.
引用
收藏
页码:472 / 478
页数:7
相关论文
共 38 条
[1]   CYTOPHOTOMETRY [J].
AUER, G ;
ASKENSTEN, U ;
AHRENS, O .
HUMAN PATHOLOGY, 1989, 20 (06) :518-527
[2]  
BEAHRS OH, 1997, MANUL STAGING CANC
[3]  
Clark JL, 2000, AM SURGEON, V66, P502
[4]   Prediction of response to primary chemotherapy for operable breast cancer [J].
Colleoni, M ;
Orvieto, E ;
Nolé, F ;
Orlando, L ;
Minchella, I ;
Viale, G ;
Peruzzotti, G ;
Robertson, C ;
Noberasco, C ;
Galimberti, V ;
Sacchini, V ;
Veronesi, P ;
Zurrida, S ;
Orecchia, R ;
Goldhirsch, A .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (04) :574-579
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]   MORPHOLOGY OF MALE BREAST-CARCINOMA IN THE EVALUATION OF PROGNOSIS [J].
CUNHA, F ;
ANDRE, S ;
SOARES, J .
PATHOLOGY RESEARCH AND PRACTICE, 1990, 186 (06) :745-750
[7]   Male breast cancer: Results of the treatments and prognostic factors in 397 cases [J].
Cutuli, B ;
Lacroze, M ;
Dilhuydy, JM ;
Velten, M ;
DeLafontan, B ;
Marchal, C ;
Resbeut, M ;
Graic, Y ;
Campana, F ;
MonchoBernier, V ;
DeGislain, C ;
Tortochaux, J ;
Cuillere, JC ;
RemeSaumon, M ;
NGuyen, TD ;
Lesaunier, F ;
LeSimple, T ;
Gamelin, E ;
Hery, M ;
Berlie, J .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) :1960-1964
[8]   Decay of androgen receptor immunoreactivity in archived tissue by using monoclonal antibody F39.4.1 [J].
Dash, RC ;
Ballo, MS ;
Layfield, LJ .
APPLIED IMMUNOHISTOCHEMISTRY, 1998, 6 (03) :145-149
[9]   MATHEMATICAL-ANALYSIS OF DNA DISTRIBUTIONS DERIVED FROM FLOW MICROFLUOROMETRY [J].
DEAN, PN ;
JETT, JH .
JOURNAL OF CELL BIOLOGY, 1974, 60 (02) :523-527
[10]   Breast cancer in men [J].
Donegan, WL ;
Redlich, PN .
SURGICAL CLINICS OF NORTH AMERICA, 1996, 76 (02) :343-&